NCT04245241

Brief Summary

This study aimed to determine the effects of HFNC therapy on lung recruitment and lung strain change assessed by electrical impedance tomography (EIT)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2018

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 20, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 28, 2020

Completed
Last Updated

January 28, 2020

Status Verified

January 1, 2020

Enrollment Period

1.2 years

First QC Date

January 20, 2020

Last Update Submit

January 25, 2020

Conditions

High-flow Nasal CannulaElectrical Impedance Tomography

Outcome Measures

Primary Outcomes (1)

  • lung regional ventilation distribution

    lung regional ventilation distribution measured by EIT

    minute 80

Interventions

High-flow nasal cannula (HFNC)OTHER

24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

adult critically ill patients, who received a HENC therapy within 24 h after the extubation, were enrolled.

You may qualify if:

  • Patient who received a HENC therapy within 24 h after the extubation

You may not qualify if:

  • Aged \<18 years
  • Pregnancy
  • Body mass index (BMI) over 50 kg/m2
  • ribcage malformation .any contraindication of using EIT monitoring (automatic implantable cardioverter defibrillator, chest skin injury, etc.).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,

Beijing, Beijing Municipality, 100730, China

Location

Related Publications (1)

  • Zhang R, He H, Yun L, Zhou X, Wang X, Chi Y, Yuan S, Zhao Z. Effect of postextubation high-flow nasal cannula therapy on lung recruitment and overdistension in high-risk patient. Crit Care. 2020 Mar 6;24(1):82. doi: 10.1186/s13054-020-2809-7.

    PMID: 32143664DERIVED

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 20, 2020

First Posted

January 28, 2020

Study Start

May 1, 2018

Primary Completion

July 1, 2019

Study Completion

November 1, 2019

Last Updated

January 28, 2020

Record last verified: 2020-01

Locations

CN(1)